[SP] Impact of Isoflurane and Desflurane on Recovery Time and Postoperative Nausea in Patients Undergoing Laparoscopic Cholecystectomy

SLCTR Registration Number

SLCTR/2026/001

Date of Registration

02 Jun 2026

The date of last modification

Jun 04, 2026


Application Summary

Scientific Title of Trial

[SP] Impact of Isoflurane and Desflurane on Recovery Time and Postoperative Nausea in Patients Undergoing Laparoscopic Cholecystectomy

Public Title of Trial

What is the effect of isoflurane compared to desflurane on recovery time and postoperative nausea in patients undergoing laparoscopic cholecystectomy?

Disease or Health Condition(s) Studied

Postoperative nausea and vomiting, Laparascopic cholecystectomy

Scientific Acronym

None

Public Acronym

None

Brief title

Isoflurane vs. Desflurane: Effects on Recovery and Nausea After Laparoscopic Cholecystectomy

Universal Trial Number

U1111-1317-9971

Any other number(s) assigned to the trial and issuing authority

IRB Approval 13/Trg/83/2024


Trial Details

What is the research question being addressed?

What is the effect of isoflurane compared to desflurane on recovery time and postoperative nausea in patients undergoing laparoscopic cholecystectomy?

Type of study

Interventional

Study design

Allocation

Randomized controlled trial

Masking

Single blinded

Persons who are masked

Participants

Assignment

Single

Control

Uncontrolled

Purpose

Other

Study Phase

Phase 2-3

Intervention(s) planned

Study setting: Combined Military Hospital Multan Method of randomization into study arms: Simple randomization Unit of randomization: Individual Patient Method of sequence generation: Computer-generated randomization A total of 110 patients aged 18 years and above undergoing planned laparoscopic cholecystectomy will randomized into two equal groups of 55 patients each. Intervention: Isoflurane, Dose: 1.2–1.5 MAC (Minimum Alveolar Concentration) Route: inhalational, used for anesthesia maintenance, given for the duration of the intraoperative period, as continuous maintenance until surgery completion). Control: Desflurane Dose: 1.3–1.5 Minimum Alveolar Concentration (MAC) Route: inhalational, used for anesthesia maintenance, given for the duration of the intraoperative period, as continuous maintenance until surgery completion). Induction protocol for both groups: vi. Midazolam 0.02 mg/kg IV (premedication) vii. Propofol 2 mg/kg IV (induction) viii. Fentanyl 2 µg/kg IV (analgesia) ix. Rocuronium 0.6 mg/kg IV (muscle relaxation and intubation) x. Standard monitoring during and after procedure Participants will be blinded to the intervention status

Inclusion criteria

Age >18 years. Males and females Undergoing planned laparoscopic cholecystectomy. ASA (American Society of Anesthesiologists) status I or II. ASA-I : completely healthy individual with no history of smoking or no prior alcohol use. ASA-II: patient with a mild systemic disease but without a major functional limitation (severe renal or hepatic dysfunction).

Exclusion criteria

BMI >35 kg/m² Chronic use of antiemetic Diagnosed severe hepatic or renal dysfunction History of hypersensitivity to inhalational anesthetics

Target number/sample size

100


Primary outcome(s)

Outcome and metrics/method of measurement

1. Postoperative recovery time The Modified Aldrete Scoring system will be used. A score of ?9 will be used as a reference to discharge the patient from the Post-anesthesia Care Unit, and the time from discontinuation of anesthetic agent to discharge will be measured

Timepoint of measurement

[Till time of discharge]
2. Incidence of postoperative nausea and vomiting within the first 24 hours postoperatively.
[Incidence of the episode of vomiting and nausea will be recorded during the early (0-6 hours) and late phase (6-24 hours).]

Secondary outcome

Outcome and metrics/method of measurement

1. Secondary - 01 Incidence of postoperative nausea and vomiting within the first 24 hours postoperatively.

Timepoint of measurement

[Test time]
2. Secondary - 02 Incidence of postoperative nausea and vomiting within the first 24 hours postoperatively.
[]

Countries of recruitment

Sri Lanka, Pakistan

Anticipated start date

2025-09-06

Anticipated end date

2026-03-06

Recruitment status

Recruiting

Funding source

Investigator funded

Regulatory Approval

None


Ethics approval

Status

Approved

Date of Approval

2026-03-03

Approval Number

3/Trg/83/2024

Details of Ethics Review Committee

Name: Institutional Review Board & Ethical Committee CMH Multan Institute of Medical Sciences
Institutional Address: Ghaus ul Azam Road? near Naseem Hayat Rd, Pia Colony, Multan, Punjab, Pakistan
Phone: (061) 9201703 77777
Email: administration@cims.pk

Contact & Sponsor Information

Contact person for Scientific Queries/Principal Investigator

Inshal Jawed
General Physician
Mission Rd, New Labour Colony Nanakwara, Karachi, Karachi City, Sindh, Pakistan
Tel (Office): +92 341 2636484
Email: inshaljwd@gmail.com
Web: https://testweb.em

Contact Person for Public Queries

Inshal Jawed
General Physician
Mission Rd, New Labour Colony Nanakwara, Karachi, Karachi City, Sindh, Pakistan
Tel (Office): +92 341 2636484
Email: inshaljwd@gmail.com
Web: https://testweb.em

Primary study sponsor/organization

Test name
test
Test

Secondary study sponsor (If any)

Trial Completion details

Do the investigators plan to share identified individual clinical trial participant-level data (IPD)?

No

IPD sharing plan description

Study protocol available

No

Protocol version and date

Not Available

Protocol URL

Not Available


Results

Results summary available

No

Date of posting results

Date of study completion

Final sample size

Date of first publication

Link to results

Brief summary of results

Trial Options
Duplicate Registration(s)